Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02898077 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | completed | Phase 3 | 440 | Eli Lilly and CompanyINDUSTRY | 4 | Jun 14, 2022 | clinicaltrials |
| NCT02370498 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | completed | Phase 3 | 592 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2022 |
| clinicaltrials |
| NCT05231382 | Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma | unknown | Phase 3 | 426 | Sun Yat-sen UniversityOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05220020 | TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer | unknown | Phase 3 | 299 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT04465734 | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC | withdrawn | Phase 3 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT02794337 | TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer(TACE-SBRT) | unknown | Phase 2 / Phase 3 | 67 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05268692 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | recruiting | Phase 2 / Phase 3 | 500 | Kochi UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT01962246 | Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction(A-C) | completed | Phase 2 / Phase 3 | 169 | Hebei Medical UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03605706 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT04617821 | AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer | unknown | Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT02192671 | HR Versus RFA for HCC in Patients With PHT(HR-HCC/PHT) | unknown | Phase 3 | 120 | Guangxi Medical UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT03988998 | Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma | unknown | Phase 3 | 100 | Guangxi Medical UniversityOTHER | 0 | Jan 18, 2022 | clinicaltrials |
| NCT03338647 | SBRT or TACE for Advanced HCC | unknown | Phase 3 | 180 | University of AarhusOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer(HiQuality) | terminated | Phase 3 | 235 | Merit Medical Systems, Inc.INDUSTRY | 5 | Nov 30, 2021 | clinicaltrials |
| NCT04969731 | Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | recruiting | Phase 3 | 408 | GC Cell CorporationINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT04595864 | Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation | recruiting | Phase 3 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT05056337 | Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | unknown | Phase 3 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT02314117 | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer(RAINFALL) | completed | Phase 3 | 645 | Eli Lilly and CompanyINDUSTRY | 20 | Aug 26, 2021 | clinicaltrials |
| NCT00487695 | Confocal Endomicroscopy for Barrett's Esophagus(CEBE) | completed | Phase 3 | 46 | Johns Hopkins UniversityOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT01655693 | Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma(ReLive) | completed | Phase 3 | 397 | Valerio TherapeuticsINDUSTRY | 11 | Jun 2, 2021 | clinicaltrials |
| NCT04909866 | The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study | unknown | Phase 2 / Phase 3 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT03536182 | Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer(CIPHER) | withdrawn | Phase 3 | 0 | University of Texas Southwestern Medical CenterOTHER | 2 | May 26, 2021 | clinicaltrials |
| NCT01455831 | Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer(PERIOP-01) | completed | Phase 3 | 616 | Ottawa Hospital Research InstituteOTHER | 3 | May 17, 2021 | clinicaltrials |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib(CELESTIAL) | completed | Phase 3 | 707 | ExelixisINDUSTRY | 19 | May 6, 2021 | clinicaltrials |
| NCT01887717 | Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein(YES-P) | terminated | Phase 3 | 36 | Boston Scientific CorporationINDUSTRY | 6 | Apr 21, 2021 | clinicaltrials |
| NCT04835064 | Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. | unknown | Phase 3 | 600 | Fudan UniversityOTHER | 0 | Apr 8, 2021 | clinicaltrials |
| NCT01755767 | Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy(METIV-HCC) | completed | Phase 3 | 383 | Daiichi SankyoINDUSTRY | 16 | Apr 6, 2021 | clinicaltrials |
| NCT04167293 | Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)(ISBRT01) | unknown | Phase 2 / Phase 3 | 116 | Mian XIOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03649035 | Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma | withdrawn | Phase 3 | 0 | Istituto Clinico HumanitasOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT04803019 | Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma(RAD-18-TAcE) | unknown | Phase 3 | 154 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT04665609 | Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC | unknown | Phase 3 | 80 | Chinese PLA General HospitalOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT02460991 | A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma(SOLACE) | terminated | Phase 3 | 2 | Boston Scientific CorporationINDUSTRY | 1 | Feb 12, 2021 | clinicaltrials |
| NCT04229355 | DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma | unknown | Phase 3 | 90 | Guangxi Medical UniversityOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT03794440 | A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | unknown | Phase 2 / Phase 3 | 595 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04687163 | Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial | unknown | Phase 3 | 400 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04667351 | HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial | unknown | Phase 3 | 400 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03898921 | RFA vs. SBRT for Small HCC | unknown | Phase 3 | 270 | Sun Yat-sen UniversityOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT01107639 | Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery | completed | Phase 3 | 297 | Swiss Cancer InstituteOTHER | 5 | Oct 20, 2020 | clinicaltrials |
| NCT04546802 | HepATocellular Cancer Hcv Therapy Study(HATCHeT) | withdrawn | Phase 3 | 0 | Bayside HealthOTHER_GOV | 0 | Sep 14, 2020 | clinicaltrials |
| NCT01774344 | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma(RESORCE) | completed | Phase 3 | 573 | BayerINDUSTRY | 21 | Aug 20, 2020 | clinicaltrials |
| NCT04167007 | FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX(GEMFOX) | unknown | Phase 3 | 400 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT03642561 | Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE | unknown | Phase 2 / Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT02169765 | HR Versus RFA for Early Stage HCC(ARTC-HCC) | unknown | Phase 3 | 120 | Guangxi Medical UniversityOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03974074 | Albumin for Hepatocellular Carcinoma | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT02971345 | Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus | unknown | Phase 3 | 253 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03300609 | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab | terminated | Phase 3 | 4 | University of Southern CaliforniaOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT02545504 | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(GAMMA-1) | completed | Phase 3 | 432 | Gilead SciencesINDUSTRY | 16 | May 26, 2020 | clinicaltrials |
| NCT03780049 | HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B | unknown | Phase 3 | 304 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT04392700 | A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection | unknown | Phase 3 | 706 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 14, 2022source: clinicaltrials